Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

ETV1 (ets variant 1)

Written2013-02Yu Chen, Ping Chi
Human Oncology, Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York, Avenue, New York, NY 10065, USA

(Note : for Links provided by Atlas : click)

Identity

Other aliasER81
LocusID (NCBI) 2115
Atlas_Id 73
Location 7p21.2  [Link to chromosome band 7p21]
Location_base_pair Starts at and ends at bp from pter
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
ACSL3 (2q36.1) / ETV1 (7p21.2)BMPR1B (4q22.3) / ETV1 (7p21.2)CANT1 (17q25.3) / ETV1 (7p21.2)
ERO1A (14q22.1) / ETV1 (7p21.2)ETV1 (7p21.2) / CPED1 (7q31.31)ETV1 (7p21.2) / ERG (21q22.2)
ETV1 (7p21.2) / EWSR1 (22q12.2)ETV1 (7p21.2) / HMGN2P46 (15q21.1)ETV1 (7p21.2) / HNRNPA2B1 (7p15.2)
ETV1 (7p21.2) / SLC45A3 (1q32.1)ETV1 (7p21.2) / SMG6 (17p13.3)ETV1 (7p21.2) / TMPRSS2 (21q22.3)
ETV1 (7p21.2) / TP53 (17p13.1)EWSR1 (22q12.2) / ETV1 (7p21.2)FOXP1 (3p13) / ETV1 (7p21.2)
FUBP1 (1p31.1) / ETV1 (7p21.2)HMGN2P46 (15q21.1) / ETV1 (7p21.2)HNRNPA2B1 (7p15.2) / ETV1 (7p21.2)
KLK2 (19q13.33) / ETV1 (7p21.2)MIPOL1 (14q13.3) / ETV1 (7p21.2)OR51E2 (11p15.4) / ETV1 (7p21.2)
SLC30A4 (15q21.1) / ETV1 (7p21.2)SLC45A3 (1q32.1) / ETV1 (7p21.2)TMPRSS2 (21q22.3) / ETV1 (7p21.2)

DNA/RNA

 
  The ETV1 gene locus is on the p arm of chromosome 7 (7p21.3), spanning from 13930854 to 14031050 (Feb. 2009 GRCh37/hg19).
Description The ETV1 (ETS-translocation variant 1) gene belongs to the PEA3-subfamily of erythroblast transformation-specific (ETS)-family of transcription factors. It is located on chromosome 7p21.3, consisting of 13 exons and spanning approximately 100 kb DNA in length (Coutte et al., 1999).
Transcription ETV1 has 7 Refseq transcripts that are generated by alternative splicing and alternative transcriptional initiation.
Pseudogene No pseudogene reported.

Protein

 
  Schematics of ETV1 and PEA3-subfamily homolog, ETV4 and ETV5. Transcriptional activation acidic domains are in grey and ETS DNA binding domains are in black (adapted from Oh et al., 2012).
Description ETV1 belongs to the PEA3-subfamily of erythroblast transformation-specific (ETS)-family of transcription factors. There are 7 protein isoforms of ETV1, ranging from 374 amino acids to 477 amino acids (~55 kD).
Expression The ETV1 protein is physiologically expressed in the central nervous system including the developing propioceptive neurons, the motor neurons and the dopaminergic neurons (Arber et al., 2000; Flames and Hobert, 2009). ETV1 is also expressed in the inner core cells of the Pacinian corpuscle (Sedy et al., 2006) and in the interstitial cells of Cajal (Chen et al., 2007; Chi et al., 2010). Pathologically, the ETV1 protein is aberrantly expressed in a subset of melanoma and prostate cancer through genomic rearrangements (Jané-Valbuena et al., 2010; Tomlins et al., 2005), or abnormally highly expressed in gastrointestinal stromal tumor (GIST) through high endogenous expression and protein stabilization by active MAP kinase signaling (Chi et al., 2010), or partially highly expressed as part of an oncogenic fusion protein-EWSR1-ETV1-in Ewing sarcoma (Jeon et al., 1995).
Localisation Nucleus.
Function ETV1 belongs to the ETS (E-twenty-six) family of transcription factors and the PEA3 subfamily transcription factors (ETV1, ETV4 and ETV5). It specifically recognizes the GGAA core consensus DNA motif in the genome and mediates transcriptional activation and repression of target genes in cell type and cell lineage-specific contexts. ETV1 is critical in the normal development of a functional sensory-motor circuitry in the spinal cord (Arber et al., 2000), the specification of a group of specialized dopaminergic neurons in the central nervous system (Flames and Hobert, 2009), the normal development of the Pacinian corpuscle (Sedy et al., 2006), and the normal development and specification of the subclasses of interstitial cells of Cajal localized in the circular muscle and in the myenteric plexus (Chi et al., 2010). ETV1 contributes to the pathogenesis of a number of cancer types through 1) aberrantly overexpression in melanoma and prostate cancer via genomic rearrangement (Jané-Valbuena et al., 2010; Tomlins et al., 2007; Tomlins et al., 2005), 2) abnormal protein stabilization in GIST (Chi et al., 2010), 3) formation of the oncogenic fusion protein EWSR1-ETV1 in Ewing sarcoma (Jeon et al., 1995).
Homology A member of the ETS-family transcription factor and the PEA3 subfamily transcription factors , with most sequence homology to ETV5 and ETV4.

Mutations

Note No validated known mutations.

Implicated in

Note
  
Entity Ewing sarcoma
Prognosis The prognostic relevance remains to be determined.
Cytogenetics Ewing sarcoma translocation, t(7;22)(p22;q12) that fused EWSR1 to the ETV1 gene (Jeon et al., 1995).
Hybrid/Mutated Gene EWSR1-ETV1 fusion gene accounts for ~1% of all Ewing sarcomas. The majority of Ewing sarcoma fusion genes are EWSR1-FLI1 (~85%) and EWSR1-ERG (~10%).
Abnormal Protein EWSR1-ETV1 fusion protein that fuses the first 7 exons of EWSR1 to the last 3-4 exons of ETV1 (exons 10 or 11-exon 13).
 
Common breakpoints of the EWS-ETV1 fusion. DNA-BD: DNA binding domain; Pro: proline-rich activation domain; PTD: pointed domain; RGG: arginine-glycine-glycine-rich region; RRM: RNA recognition motif; SYQG: serine-tyrosine-glutamine-glycine-rich region that has a high transactivation potential; ZN: zinc finger. Adapted from Janknecht, 2005.
Oncogenesis The EWSR1-ETS (EWSR1-FLI1, EWSR1-ETV1, EWSR1-ERG, etc) fusion proteins are thought to be the "oncogenic drivers" in Ewing sarcoma. EWSR1-FLI1 and EWSR1-ERG have been modeled in cell lines demonstrating the requirement of the oncogenic fusion proteins for Ewing sarcoma cell line growth and survival. The EWSR1-ETV1 fusion protein has not been modeled.
  
  
Entity Prostate cancer
Prognosis ETV1 fusion seems to confer a poorer prognosis in several studies.
 
Typical breakpoint in prostate cancer fusions.
Oncogenesis ETV1 is aberrantly overexpressed in prostate cancer through genomic rearrangements that result in overexpression of a truncated ETV1 or full-length ETV1. ETV1 is required for the growth of ETV1-positive prostate cancer cells and ETV1 overexpression confers invasiveness prostate cancer cells (Tomlins et al., 2007; Tomlins et al., 2005).
  
  
Entity Melanoma
Prognosis The prognostic relevance remains to be determined.
Oncogenesis ETV1 is amplified in 13% of primary and 18% of metastatic melanomas, which results in aberrant overexpression. ETV1 is required for growth and proliferation of melanoma cells with ETV1 amplification and it cooperates with oncogenic NRAS (G12D) for tumorigenesis in mice (Jané-Valbuena et al., 2010).
  
  
Entity Gastrointestinal stromal tumor (GIST)
Prognosis The prognostic relevance remains to be determined.
Oncogenesis ETV1 is naturally highly expressed and is required for the development of the interstitial cells of Cajal (ICCs) in the gastrointestinal tract that are the precursor cells of GIST. It is also highly expressed and required for the growth, survival and tumorigenesis of GISTs. It drives a core transcriptional program that is conserved in ICC and GIST. ETV1 protein level is stabilized by active KIT and downstream MAP kinase signaling pathways and cooperates with mutant KIT in GIST pathogenesis (Chi et al., 2010).
  

Breakpoints

 

To be noted

None.

Bibliography

ETS gene Er81 controls the formation of functional connections between group Ia sensory afferents and motor neurons.
Arber S, Ladle DR, Lin JH, Frank E, Jessell TM.
Cell. 2000 May 26;101(5):485-98.
PMID 10850491
 
Differential gene expression in functional classes of interstitial cells of Cajal in murine small intestine.
Chen H, Ordog T, Chen J, Young DL, Bardsley MR, Redelman D, Ward SM, Sanders KM.
Physiol Genomics. 2007 Nov 14;31(3):492-509. Epub 2007 Sep 25.
PMID 17895395
 
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL.
Nature. 2010 Oct 14;467(7317):849-53. doi: 10.1038/nature09409. Epub 2010 Oct 3.
PMID 20927104
 
Characterization of the human and mouse ETV1/ER81 transcription factor genes: role of the two alternatively spliced isoforms in the human.
Coutte L, Monte D, Imai K, Pouilly L, Dewitte F, Vidaud M, Adamski J, Baert JL, de Launoit Y.
Oncogene. 1999 Nov 4;18(46):6278-86.
PMID 10597226
 
Gene regulatory logic of dopamine neuron differentiation.
Flames N, Hobert O.
Nature. 2009 Apr 16;458(7240):885-9. doi: 10.1038/nature07929. Epub 2009 Mar 15.
PMID 19287374
 
An oncogenic role for ETV1 in melanoma.
Jane-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, Hahn WC, Duncan LM, Rubin MA, Fisher DE, Garraway LA.
Cancer Res. 2010 Mar 1;70(5):2075-84. doi: 10.1158/0008-5472.CAN-09-3092. Epub 2010 Feb 16.
PMID 20160028
 
EWS-ETS oncoproteins: the linchpins of Ewing tumors.
Janknecht R.
Gene. 2005 Dec 19;363:1-14. Epub 2005 Oct 3.
PMID 16202544
 
A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN.
Oncogene. 1995 Mar 16;10(6):1229-34.
PMID 7700648
 
ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.
Oh S, Shin S, Janknecht R.
Biochim Biophys Acta. 2012 Aug;1826(1):1-12. doi: 10.1016/j.bbcan.2012.02.002. Epub 2012 Mar 8.
PMID 22425584
 
ETS transcription factor ER81 is required for the Pacinian corpuscle development.
Sedy J, Tseng S, Walro JM, Grim M, Kucera J.
Dev Dyn. 2006 Apr;235(4):1081-9.
PMID 16493690
 
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.
Nature. 2007 Aug 2;448(7153):595-9.
PMID 17671502
 

Citation

This paper should be referenced as such :
Chen, Y ; Chi, P
ETV1 (ets variant 1)
Atlas Genet Cytogenet Oncol Haematol. 2013;17(7):483-486.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/ETV1ID73ch7p21.html


Other Leukemias implicated (Data extracted from papers in the Atlas) [ 2 ]
  12p abnormalities in myeloid malignancies
t(8;20)(p11;q13) KAT6A/NCOA3


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 14 ]
  Soft Tissues: Angiomatoid fibrous histiocytoma
Bone tumors: an overview
Soft Tissues: Ewing's tumors/Primitive neurectodermal tumors (PNET)
Prostate tumors: an overview
Soft tissue tumors: an overview
t(1;7)(p31;p21) FUBP1/ETV1
t(4;7)(q22;p21) BMPR1B/ETV1
t(7;7)(p15;p21) HNRNPA2B1/ETV1
t(7;11)(p21;p15) OR51E2/ETV1
t(7;15)(p21;q21) HMGN2P46/ETV1
t(7;17)(p21;p13) HERVK17/ETV1
t(7;17)(p21;p13) AX747630/ETV1
t(7;19)(p21;q13) KLK2/ETV1
t(7;22)(p21;q11) HERVK22Q11/ETV1


External links

Nomenclature
Cards
AtlasETV1ID73ch7p21.txt
Aliases
Genomic and cartography
Gene and transcription
RefSeq transcript (Entrez)
RefSeq genomic (Entrez)
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
BioGPS (Tissue expression)2115
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Protein Interaction databases
Ontologies - Pathways
Clinical trials, drugs, therapy
Miscellaneous
canSAR (ICR) (select the gene name)
Probes
Litterature
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Oct 18 17:35:41 CEST 2018

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.